Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA’s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment.

Following Prosigna’s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) breast cancer who meet the applicable Medicare criteria, including stage I or II disease with 0-3 positive lymph nodes.¹

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.